Videos

“The complete clinical response rate of 48% was somewhat surprising, although consistent with our assumptions in terms of the statistical design of the study,” says Matthew Galsky, MD.

Urologist Amy M. Pearlman, MD, discusses how she uses social platforms such as Twitter, Facebook, and Tiktok to entertain and inform.

Dr. Michael Devitt, discusses whether circulating tumors cells are ready for primetime as a diagnostic/prognostic biomarker in urothelial carcinoma.

The study follows a successful phase 1b/2 study, data from which were presented at the 2021 ASCO Annual Meeting.

“It's important for any urologist to gain a broader exposure and awareness to the tools and techniques available to help improve efficiency in the operating room and reduce the amount of wasteful time in between cases,” says Niki N. Parikh, MD, MBA, MSBA.

Sivakumar was a researcher on a study presented at the 2021 ASCO Annual Meeting that assessed ancestry, patterns of gene alterations, comprehensive genomic profiling, and treatment patterns in nearly 12,000 patients with prostate cancer.

Robert A. Figlin, MD, discusses results from the phase 2 CANTATA study of cabozantinib plus telaglenastat in patients with advanced/metastatic renal cell carcinoma.

Laura Bukavina, MD, MPH, and Justin Dubin, MD, also discuss their own usage of social media and share advice for medical professionals using social media.

Two experts in the management of prostate cancer provide key insight into the value of blood and urine liquid biopsy tests when deciding whether to perform a prostate tissue biopsy.

Thought leaders in the management of prostate cancer build a discussion on the challenges associated with the use of MRI to diagnose prostate cancer including insurance coverage and patient discomfort.

Lantheus, the developer of piflufolastat F 18, selected oncology provider GenesisCare to administer the first commercially available dose of the agent.

“I think the data from this particular abstract pretty much reinforce that if you get avelumab as maintenance therapy, the time that patients spend in first- and second-line therapy is prolonged compared to patients who get best supportive care,” says Petros Grivas, MD, PhD.

Chung-Han Lee, MD, PhD, discusses the ongoing open-label phase 2 KEYNOTE-B61 study of frontline pembrolizumab plus lenvatinib in non-clear cell renal cell carcinoma.

“A lot of medicine that you do in person is very provider-centric in the sense that you tend to just walk from room to room and see patients, whereas with virtual care, you need to change the workflow a little bit,” says Chad Ellimoottil, MD, MS.

Petros Grivas, MD, PhD, discusses posthoc findings from the phase 3 JAVELIN Bladder 100 trial presented during the 2021 ASCO Annual Meeting.

Virtual men’s health options have “improved access for patients who otherwise cannot reach doctors or who are otherwise embarrassed to go see someone in person,” says Ranjith Ramasamy, MD.

Toni K. Choueiri, MD, discusses the clinical and regulatory implications of the phase 3 KEYNOTE-564 trial, which explored pembrolizumab following nephrectomy in patients with clear cell renal cell carcinoma.

Figlin shares his expert observations on important questions that still remain, despite the positive results of the trial.

In this video, Ranjith Ramasamy, MD, explains that although testosterone therapy comes with risks, “these risks appear to be very, very small.”

Experts urologists, David Albala, MD and Judd W. Moul, MD, compare the utility of a variety of blood and urine tests for screening and diagnosing prostate cancer.

Key opinion leaders in urology provide an overview of the prevalence of prostate cancer and discuss the importance of screening and risk assessment tools like the Prostate-Specific Antigen (PSA) test.

Neal D. Shore, MD, discusses results from the phase 2 ODENZA trial which explored patient preference between darolutamide and enzalutamide in men with metastatic castration-resistant prostate cancer.

In this video, lead author Edmund M. Qiao discusses study results presented during the 2021 ASCO Annual Meeting which showed an association between increased prostate-specific antigen screening and improved outcomes in younger African American patients.

“Patients of African ancestry were actually less likely to receive comprehensive genomic profiling earlier in their treatment course than patients of European ancestry, and…patients of African ancestry [were] less likely to be treated in clinical trials,” says Jessica Lee, MS.

“Recurrence of urothelial cancer, in particular metastatic recurrence, is associated with a detriment in quality of life in this exploratory analysis,” says Matthew Galsky, MD.

Nizar M. Tannir, MD, discusses results from the phase 2 CANTATA study of cabozantinib plus telaglenastat in patients with advanced/metastatic renal cell carcinoma.

The study explored pembrolizumab versus placebo following nephrectomy in patients with clear cell renal cell carcinoma.

Neeraj Agarwal, MD, discusses results from the phase 3 SWOG S1216 trial, which compared ADT plus the novel agent TAK-700 or bicalutamide in patients with newly diagnosed metastatic hormone-sensitive prostate cancer.

Darolutamide is FDA-approved for the treatment of patients with nonmetastatic castration-resistant prostate cancer.

“It could be that the integration of a new treatment modality into the bladder-sparing arena is a tipping point that is needed to really have the community embrace this as a reasonable option for patients with bladder cancer,” says Matthew Galsky, MD.